Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCB-201 is an induced pluripotent stem cell (iPSC)-derived artificial platelet-like particle (i-aPLP) developed by Dewcell Biotherapeutics. It is engineered using the company's proprietary en-aPLT™ and i-aPLP™ platforms to mimic the biological functions of natural platelets, particularly their role in hemostasis and tissue regeneration. Unlike traditional donor-derived platelets, DCB-201 is designed as a standardized, off-the-shelf therapeutic product that avoids the limitations of short shelf life and supply instability. The primary therapeutic focus for DCB-201 is regenerative medicine, specifically targeting wound healing and skin regeneration by delivering platelet-like signaling and growth factors to damaged tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DCB-201.